# US 2004/0082005 A1 · Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082005 A1
- Document ID: US20040082005A1
- Status: Published application
- Kind: A1
- Application number: 10/654,298
- Filed: 2003-09-03
- Published: 2004-04-29
- Earliest claimed: 2002-09-03
- Assignees: Charles S. Cobbs; Luaihati Harkins
- Inventors: Charles S. Cobbs; Lualhatil E. Harkins
- Web page: https://patentgrep.com/patent/US20040082005A1

## CPC

- G01N 33/56994: {Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/705: {for herpetoviridae, e.g. herpes simplex, varicella zoster}
- C12Q 2600/112: Disease subtyping, staging or classification
- G01N 2333/045: Cytomegalovirus
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure shows human cytomegalovirus (HCMV) is strongly associated with a variety of cancers in humans. In addition, the present disclosure shows a specific strain of HCMV, HDu, is associated with several types of cancer. The identification cells harboring certain strains of HCMV, such as HDu, will provide a novel mechanism to identify cells that are at risk for undergoing oncogenesis. Novel strategies for detecting HCMV are also disclosed.

## Claims

### Claim 1

A method for detecting the presence of a HCMV in a tissue sample, the method comprising the steps of:
a. providing said tissue sample suspected of containing HCMV from said subject, said tissue sample being embedded in a paraffin matrix, and mounting said tissue sample to a transparent support;
b. de-paraffinizing said tissue sample;
c. subjecting said tissue sample an epitope conditioning procedure to reduce epitope variability in said tissue sample;
d. subjecting said tissue sample to an antigen retrieval procedure,
e. contacting said tissue sample with at least one antibody capable of binding to at least one epitope of HCMV to form an antibody-epitope complex, under conditions suitable for binding of said antibody with said epitope;
f. detecting said antibody epitope complex.

### Claim 2 (depends on 1)

The method of claim 1 where the tissue sample is obtained from a glial, a breast, a prostate, a colon, a cervical or an ovarian tissue.

### Claim 3 (depends on 1)

The method of claim 1 where the paraffin matrix has a thickness selected from the group consisting of 3 microns, 4 microns, 5 microns, 6 microns and 7 microns.

### Claim 4 (depends on 1)

The method of claim 1 where the tissue sample is obtained from glial tissue and the paraffin matrix has a thickness of 6 microns.

### Claim 5 (depends on 1)

The method of claim 1 where the tissue sample is obtained from breast, prostate, colon, cervical or ovarian tissue and the paraffin matrix has a thickness of 4 microns or 5 microns.

### Claim 6 (depends on 1)

The method of claim 1 where the de-paraffinizing said tissue sample comprises rinsing said tissue samples in xylene at least one time, followed by rinsing said tissue samples at least one time in a series of ethanol solutions of decreasing concentration, said decreasing ethanol concentrations selected from the group consisting of 100%, 95%, 75% and 50%.

### Claim 7 (depends on 1)

The method of claim 1 where the epitope conditioning procedure comprises incubating said tissue sample in 10% neutral buffered formalin for a time period sufficient for epitope conditioning and subjecting said tissue samples to digestion with an enzyme.

### Claim 8 (depends on 7)

The method of claim 7 where the time period sufficient for epitope conditioning is determined by the age of the tissue sample.

### Claim 9 (depends on 8)

The method of claim 8 where the time period is selected from the group consisting of: 15 to 20 minutes for tissue sample less than 30 days old; 45 to 60 minutes for tissue samples 2 to 6 months old; 90 to 180 minutes for tissue samples 6 to 24 months old; 180 to 240 minutes for tissue samples 24 to 48 months old; and 240 to 360 minutes for tissue samples over 48 months old.

### Claim 10 (depends on 7)

The method of claim 7 where the enzyme is a pepsin or a trypsin and the digestions occurs at 37° C. for 4 to 6 minutes.

### Claim 11 (depends on 1)

The method of claim 1 where the antigen retrieval procedure comprises incubating said tissue sample in a citra buffer where the tissues samples were originally fixed with a formalin based fixative or in a distilled water where the tissue samples were originally fixed in a non-formalin based fixative for a time period sufficient for said antigen retrieval.

### Claim 12 (depends on 11)

The method of claim 11 where the time period is about 2 to 2.5 hours.

### Claim 13 (depends on 12)

The method of claim 12 where the incubation of said tissue sample with said citra buffer is takes place in a water bath having a temperature of 45-50° C. and said citra buffer is pre-warmed to a range of 85-90° C. and has a pH of 7.6.

### Claim 14 (depends on 1)

The method of claim 1 further comprising incubating said tissue sample in at least one blocking reagent selected from the group consisting of a hydrogen peroxide solution, an avidin/biotin solution and a protein blocking solution.

### Claim 15 (depends on 1)

The method of claim 1 where the at least one antibody is directed against at least one protein selected from the group consisting of IE1, IE2, pp65, or CMV late antigen.

### Claim 16 (depends on 15)

The method of claim 15 where the antibodies are diluted with common antibody diluent and used within 24 hours after dilution.

### Claim 17 (depends on 15)

The method of claim 15 where the antibodies are incubated with said tissue sample at 4-8° C. overnight in a humidified container.

### Claim 18 (depends on 1)

The method of claim 1 where the detecting step comprises incubation of the antigen-epitope complex with a secondary antibody and a signal producing reagent, said signal producing reagent comprising at least one of a labeling reagent capable of interacting with the secondary antibody, a chromogen capable of transformation by the labeling reagent to a detectable signal and a chromogen enhancer.

### Claim 19 (depends on 1)

The method of claim 1 where the epitope conditioning procedure and the antigen retrieval procedure are optimized to yield no or substantially no background when the antibody of step (e) is omitted.

### Claim 20 (depends on 1)

The method of claim 1 where the tissue samples are washed with a washing solution between the steps of the method of claim 1, said washing solution being TBS, TBST or water.

### Claim 21 (depends on 1)

The method of claim 1 where the detection is specific for a specific strain of HCMV.

### Claim 22 (depends on 21)

The method of claim 21 where the specific strain of HCMV is HDu.

### Claim 23 (depends on 21)

The method of claim 21 where the specific strain of HCMV is HDu and where the detection is specific for glycoprotein N.

### Claim 24

A method of determining if a human subject is at risk for a disease correlated with the presence of a HCMV infection, said method comprising the steps of:
a. providing a tissue sample suspected of containing HCMV from said subject;
b. determining if HCMV is present in said tissue sample.

### Claim 25 (depends on 24)

The method of claim 24 where said determining is specific for a specific strain of HMCV.

### Claim 26 (depends on 25)

The method of claim 25 where the specific strain of HCMV is HDu.

### Claim 27 (depends on 25)

The method of claim 25 where the specific strain of HCMV is HDu and where the determining is specific for glycoprotein N.

### Claim 28 (depends on 24)

The method of claim 24 further comprising providing a negative control tissue and determining whether a level of HCMV in said tissue sample is greater than a level of HCMV in said negative control tissue.

### Claim 29 (depends on 24)

The method of claim 24 where the disease is selected from the group consisting of glioma, breast cancer, prostate cancer, colon cancer, cervical cancer or ovarian cancer.

### Claim 30 (depends on 1, 24)

The method of claim 24 where said determining is accomplished using the method of claim 1.

### Claim 31 (depends on 1, 28)

The method of claim 28 where said determining is accomplished using the method of claim 1.

### Claim 32 (depends on 24)

The method of claim 24 where the tissue sample is obtained from a glial, a breast, a prostate, a colon, a cervical or an ovarian tissue.

### Claim 33

An immunohistochemistry kit for determining the presence of a HCMV present at a low copy number in a tissue sample, said kit comprising:
a. epitope conditioning reagents, said epitope conditioning reagents comprising neutral buffered formalin (10%), and at least one enzyme for digestion of said tissue sample;
b. antigen recovery reagents, said antigen recovery reagents comprising citra buffer and distilled water;
c. HCMV control tissue reagent, said control tissue reagent comprising at least one of a positive control HCMV tissue and a negative control HCMV tissue;
d. at least one primary antibody specific for at least one epitope of HCMV;
e. at least one negative control antibody;
f. at least one secondary antibody capable of interacting with said primary and negative control antibodies; and
g. supplementary and signal producing reagents, said supplementary and signal producing reagents comprising at least one of a blocking reagent, a labeling reagent capable of interacting with the secondary antibody, a chromogen capable of transformation by the labeling reagent to produce a detectable signal and a chromogen enhancer.

### Claim 34 (depends on 33)

The kit of claim 33 further comprising instructions for use of the kit.

### Claim 35 (depends on 33)

The kit of claim 33 where the enzyme is trypsin or pepsin and the kit further comprises reagents for diluting the enzyme.

### Claim 36 (depends on 33)

The kit of claim 33 where the HCMV control tissue is supplied in a lyophilized form.

### Claim 37 (depends on 33)

The kit of claim 33 where the at least one primary antibody is specific for a specific strain of HCMV.

### Claim 38 (depends on 37)

The kit of claim 37 where the specific strain of HCMV is HDu.

### Claim 39 (depends on 37)

The kit of claim 37 where the strain is HDu and the at least one primary antibody is specific for glycoprotein N.

### Claim 40 (depends on 33)

The kit of claim 33 where the at least one antibody is directed against at least one protein selected from the group consisting of IE1, IE2, pp65, or CMV late antigen.
